RxDoctor Payments DataLook up a doctor →

Naveed Rajper, MD

Interventional Cardiology · Statesville, NCNPI 1114226354

Payments from drug & device makers

$249,726in general payments, 2019–2025

Across 354 payments — averaging $705.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$186K
  • Angiodynamics, Inc.$26K
  • AstraZeneca$20K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$7K
  • Bridgebio Pharma, Inc.$3K
  • Boston Scientific$2K
  • plus $6K from 38 others

What the payments were for

  • Consulting fees$21,0019%
  • Speaking & faculty fees$147,36866%
  • Travel & lodging$19,4669%
  • Food & beverage$9,6474%
  • Education$880%
  • Other$25,41711%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$249,726 in reported general payments places this provider in the 80th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$574,899
Medicare patients
922
Services billed
10,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol643$644,226
VyndamaxTafamidis24$548,468
XareltoRivaroxaban417$418,967
MounjaroTirzepatide188$226,550
EntrestoSacubitril/Valsartan190$208,634
EliquisApixaban156$180,665
OzempicSemaglutide167$177,647
Repatha SureclickEvolocumab180$165,210
WegovySemaglutide72$103,368
JardianceEmpagliflozin80$88,904
Rosuvastatin Calcium1,177$11,636
Metoprolol Succinate970$9,091
Ezetimibe600$8,890
DapagliflozinDapagliflozin Propanediol18$8,805
Cilostazol234$5,136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$182$729,132180 claims
AstraZenecaFarxiga$20,028$644,226643 claims
Johnson & JohnsonXarelto$219$418,967417 claims
Novo NordiskOzempic, Wegovy$186,276$281,014239 claims
Lilly USA, LLCMounjaro$78$226,550188 claims
NovartisEntresto$649$208,634190 claims
Boehringer IngelheimJardiance$151$88,90480 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in Statesville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →